BlackRock’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-3,673,443
| Closed | -$5.4M | – | 6032 |
|
|
2022
Q2 | $5.4M | Sell |
3,673,443
-7,104,595
| -66% | -$5.22M | ﹤0.01% | 3787 |
|
|
2022
Q1 | $12.4M | Buy |
10,778,038
+3,162,390
| +42% | +$5.16M | ﹤0.01% | 3464 |
|
|
2021
Q4 | $19M | Buy |
7,615,648
+71,289
| +0.9% | +$280K | ﹤0.01% | 3302 |
|
|
2021
Q3 | $38.6M | Sell |
7,544,359
-287,661
| -4% | -$1.75M | ﹤0.01% | 2833 |
|
|
2021
Q2 | $65.1M | Sell |
7,832,020
-560,038
| -7% | -$4.72M | ﹤0.01% | 2524 |
|
|
2021
Q1 | $73.1M | Buy |
8,392,058
+481,030
| +6% | +$4.98M | ﹤0.01% | 2376 |
|
|
2020
Q4 | $85.9M | Buy |
7,911,028
+238,761
| +3% | +$2.95M | ﹤0.01% | 2164 |
|
|
2020
Q3 | $91.5M | Buy |
7,672,267
+75,982
| +1% | +$1.02M | ﹤0.01% | 1935 |
|
|
2020
Q2 | $122M | Buy |
7,596,285
+770,240
| +11% | +$13.4M | ﹤0.01% | 1723 |
|
|
2020
Q1 | $106M | Sell |
6,826,045
-103,651
| -1% | -$2.23M | 0.01% | 1607 |
|
|
2019
Q4 | $170M | Buy |
6,929,696
+119,176
| +2% | +$1.77M | 0.01% | 1618 |
|
|
2019
Q3 | $70.2M | Buy |
6,810,520
+369,923
| +6% | +$4.67M | ﹤0.01% | 2088 |
|
|
2019
Q2 | $80.8M | Buy |
6,440,597
+1,552,216
| +32% | +$20M | ﹤0.01% | 2042 |
|
|
2019
Q1 | $60.6M | Sell |
4,888,381
-304,906
| -6% | -$3.41M | ﹤0.01% | 2172 |
|
|
2018
Q4 | $32M | Buy |
5,193,287
+830,815
| +19% | +$6.34M | ﹤0.01% | 2475 |
|
|
2018
Q3 | $46.2M | Buy |
4,362,472
+58,752
| +1% | +$671K | ﹤0.01% | 2419 |
|
|
2018
Q2 | $58.3M | Buy |
4,303,720
+406,541
| +10% | +$6.33M | ﹤0.01% | 2276 |
|
|
2018
Q1 | $69.2M | Sell |
3,897,179
-68,212
| -2% | -$1.15M | ﹤0.01% | 2070 |
|
|
2017
Q4 | $49.8M | Buy |
3,965,391
+579,662
| +17% | +$8.43M | ﹤0.01% | 2296 |
|
|
2017
Q3 | $64.5M | Buy |
3,385,729
+98,632
| +3% | +$1.5M | ﹤0.01% | 2114 |
|
|
2017
Q2 | $49.6M | Buy |
3,287,097
+68,466
| +2% | +$1.03M | ﹤0.01% | 2260 |
|
|
2017
Q1 | $55.2M | Buy |
3,218,631
+3,214,076
| +70,561% | +$42.8M | ﹤0.01% | 2154 |
|
|
2016
Q4 | $55K | Sell |
4,555
-8
| -0.2% | -$83 | ﹤0.01% | 2886 |
|
|
2016
Q3 | $45K | Buy |
4,563
+220
| +5% | +$2.01K | ﹤0.01% | 3014 |
|
|
2016
Q2 | $45K | Buy |
4,343
+1,214
| +39% | +$13.5K | ﹤0.01% | 2992 |
|
|
2016
Q1 | $38K | Buy |
3,129
+2,468
| +373% | +$25K | ﹤0.01% | 2518 |
|
|
2015
Q4 | $11K | Sell |
661
-198
| -23% | -$2.94K | ﹤0.01% | 2868 |
|
|
2015
Q3 | $11K | Buy |
859
+119
| +16% | +$2.4K | ﹤0.01% | 2702 |
|
|
2015
Q2 | $18K | Buy |
740
+446
| +152% | +$8.58K | ﹤0.01% | 2456 |
|
|
2015
Q1 | $6K | Hold |
294
| – | – | ﹤0.01% | 2994 |
|
|
2014
Q4 | $6K | Hold |
294
| – | – | ﹤0.01% | 3017 |
|
|
2014
Q3 | $8K | Hold |
294
| – | – | ﹤0.01% | 2880 |
|
|
2014
Q2 | $9K | Buy |
294
+99
| +51% | +$2.33K | ﹤0.01% | 2872 |
|
|
2014
Q1 | $4K | Buy |
195
+63
| +48% | +$1.91K | ﹤0.01% | 3093 |
|
|
2013
Q4 | $3K | Hold |
132
| – | – | ﹤0.01% | 3116 |
|
|
2013
Q3 | $5K | Buy |
+132
| New | +$4.47K | ﹤0.01% | 3004 |
|
Other funds holding EPZM
BlackRock's EPZM Position: Q3 2022 in Review
BlackRock sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 3,673,443 shares — an estimated $5.4M sold.
BlackRock first reported a position in EPZM in Q3 2013 and held it in 36 quarters. The position peaked at $170M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- BlackRock reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- BlackRock sold 3,673,443 Epizyme, Inc shares in Q3 2022, an estimated $5.4M.
- BlackRock first reported a position in Epizyme, Inc in Q3 2013 and held it in 36 quarters.
- BlackRock's Epizyme, Inc position peaked at $170M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.